(SGHT) Sight Sciences, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SGHT) Sight Sciences, Inc. Complete Analysis Pack
Sight Sciences Business Model Canvas: Strategy at a Glance
Unlock the full strategic blueprint behind Sight Sciences, Inc.’s business model. This concise Business Model Canvas shows how the company creates value, reaches key customers, and competes in a fast-evolving medtech market. Download the full version for deeper insights, strategic clarity, and investor-ready analysis.
Partnerships
U.S. distribution partners
Sight Sciences, Inc. uses U.S. distribution partners to extend reach beyond its direct sales force, helping it access both hospital and office-based accounts. This channel mix supports broader product availability across the U.S. market, where the company reported net revenue of $71.5 million in fiscal 2024.
Contract manufacturers and suppliers
Sight Sciences, Inc. depends on contract manufacturers and suppliers for precision parts, device assembly, and steady component flow across its two core commercial platforms, OMNI and TearCare. In regulated medtech, that matters because controlled production and traceability reduce quality risk and help keep supply continuity intact.
Clinical investigator sites
Clinical investigator sites are essential for Sight Sciences, Inc. because glaucoma affects about 80 million people worldwide, so strong clinical evidence matters for adoption. These sites help generate the data that supports physician trust, commercialization, and reimbursement in glaucoma and dry eye care.
Ophthalmology key opinion leaders
Ophthalmology key opinion leaders are a critical channel for Sight Sciences, Inc. because specialist physicians drive adoption in eye care, and their hands-on feedback helps refine training and product design across its 2 main platforms, OMNI and TearCare. They also widen awareness among surgeons and clinics, which matters in a market where physician trust often decides whether a device moves from pilot use to routine care.
- Speeds surgeon adoption
- Improves training and technique
- Shapes product refinements
- Expands clinic-level awareness
Regulatory and quality vendors
Sight Sciences, Inc. can use regulatory and quality vendors for testing, documentation, and post-market surveillance, which are core FDA medical device duties under the Quality Management System Regulation. That support lowers execution risk in the U.S. by helping keep filings, audits, and complaint handling tight.
- Supports FDA compliance work
- Reduces audit and recall risk
- Improves market launch speed
Sight Sciences’ partner network powers OMNI and TearCare growth
Sight Sciences, Inc. relies on U.S. distributors, contract manufacturers, clinical sites, and ophthalmology key opinion leaders to support OMNI and TearCare. These partners help widen access, protect quality, and build the clinical evidence behind its $71.5 million fiscal 2024 net revenue.
| Partner | Role |
|---|---|
| Distributors | Expand U.S. reach |
| Contract manufacturers | Make devices and parts |
| KOLs and sites | Support evidence and adoption |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Sight Sciences, Inc., capturing its 9 key blocks and strategic operating model.
Customizable Excel Spreadsheet
Quickly shows how Sight Sciences eases patient pain through a clear, one-page business model snapshot.
Reference Sources
Sight Sciences, Inc. reference sources provide a credible audit trail that speeds due diligence and strengthens decision-making.
Activities
Ophthalmic device R and D
Sight Sciences, Inc. puts ophthalmic device R and D at the core of its model, with innovation driving both surgical and non-surgical eye care devices. Its two flagship platforms, OMNI and TearCare, show how product design and iteration support clinical use and market growth.
Clinical evidence generation
Clinical evidence generation is central for Sight Sciences, Inc. because physicians and hospitals need proof before changing care in glaucoma and dry eye. Its adoption case depends on real-world data that shows where the products fit, how they perform, and which use cases are strongest for doctors and institutions.
Regulatory and quality management
Sight Sciences, Inc. must keep FDA-ready quality systems under 21 CFR Part 820 to support U.S. sales, with documented design controls, complaint handling, and CAPA (corrective and preventive action). In 2025/2026, this kind of control is central for every device shipped because it protects product consistency and lowers recall risk while enabling commercialization.
U.S. sales execution
Sight Sciences, Inc. relies on U.S. sales execution as its main route to market, using a direct sales force plus distribution partners to reach hospitals, medical centers, and eye care professionals. This channel is the core of commercial activity, so field coverage, account conversion, and clinician adoption drive revenue growth.
- Direct sales force drives U.S. demand
- Partners extend reach in key accounts
- Focus stays on hospitals and eye care
Physician training and support
Physician training and support are core because Sight Sciences, Inc. products need clinical onboarding before use in office and surgery. Ongoing education helps eye care teams adopt OMNI and TearCare, and post-sale support keeps utilization up as practices build repeat use.
- Clinical onboarding drives first use
- OMNI and TearCare need workflow training
- Post-sale support sustains utilization
Two Platforms, One Mission: Driving Growth in Glaucoma and Dry Eye
Sight Sciences, Inc. centers Key Activities on 2 product lines, OMNI and TearCare, with ongoing R and D, clinical evidence work, and FDA quality controls under 21 CFR Part 820. U.S. commercial execution and physician training keep adoption moving in glaucoma and dry eye.
| Key activity | Data point |
|---|---|
| Platforms | 2: OMNI and TearCare |
| Commercial reach | U.S. direct sales plus partners |
| Regulatory control | 21 CFR Part 820 |
What You See Is What You Get
Business Model Canvas
This Sight Sciences, Inc. Business Model Canvas preview is the exact same document you’ll receive after purchase, not a sample or placeholder. The file shown here is a direct snapshot of the final deliverable, with the same structure, content, and formatting. Once you complete your order, you’ll get instant access to this same ready-to-use document.
Resources
OMNI Surgical System
OMNI Surgical System is Sight Sciences, Inc.'s core adult glaucoma product and one of its main commercial assets. Used by eye surgeons to lower intraocular pressure, it addresses a disease that affects about 80 million people worldwide, including roughly 3 million in the United States.
TearCare System
TearCare System is Sight Sciences, Inc.'s wearable eyelid therapy for dry eye disease, sold through ophthalmologists and optometrists. It gives Company Name a second product line beyond glaucoma and helps broaden its addressable eye-care market.
Direct sales force
Sight Sciences, Inc. uses a U.S.-based direct sales force to cover accounts and keep physicians engaged, making it a core commercial asset. This matters because the company’s 2024 net revenue was about $82 million, and direct field selling helps drive procedure adoption in its surgeon and clinic network.
Distribution partner network
Distribution partner network extends Sight Sciences, Inc.'s reach into clinics and helps place MIGS and dry-eye products where surgeons use them. The channel matters for U.S. scale because the company still relies on a focused commercial footprint, with net revenue of $72.7 million in 2024.
- Expands clinic-level access
- Supports U.S. sales scale
- Speeds product placement
Menlo Park headquarters
Sight Sciences, Inc., founded in 2010, keeps its corporate operations in Menlo Park, California. The Menlo Park headquarters supports leadership, strategy, and administration, so it is the core site for running the business.
- Founded in 2010
- Corporate HQ: Menlo Park, California
- Supports leadership, strategy, administration
Sight Sciences’ Core Assets Power Its $82M Revenue Base
Sight Sciences, Inc.'s key resources are its OMNI Surgical System and TearCare System, plus a U.S. direct sales force that supports surgeon and clinic adoption. Menlo Park headquarters and distribution partners help run the business and widen access; 2024 net revenue was about $82 million.
| Key resource | Role | Data |
|---|---|---|
| OMNI Surgical System | Glaucoma therapy | Core adult product |
| TearCare System | Dry eye therapy | Second product line |
| Direct sales force | Commercial reach | Supports $82 million revenue |
Value Propositions
Glaucoma pressure reduction
OMNI is built for adult glaucoma patients and helps eye surgeons lower intraocular pressure, the main driver of optic nerve damage and vision loss. Glaucoma affects about 80 million people worldwide, so even small pressure cuts can matter for a very large patient base.
Dry eye disease management
Sight Sciences, Inc.'s TearCare treats dry eye disease with a wearable, eyelid-based system that applies heat to help restore meibomian gland function, addressing a chronic condition that affects an estimated 16 million U.S. adults diagnosed each year. The company said 2025 net revenue was $75.1 million, and dry eye remains a large recurring care market with ongoing treatment demand.
Two-disease portfolio
Sight Sciences, Inc. spans surgical glaucoma care and non-surgical dry eye care, so one platform reaches two large eye-care markets. Its OMNI surgery system and TearCare system each address distinct patient paths, broadening commercial reach; the company reported $81.4 million in net revenue for fiscal 2024, showing the value of this two-disease portfolio.
U.S. market availability
Sight Sciences, Inc. sells its products across the United States, giving hospitals, medical centers, and eye care professionals broad access to its glaucoma and dry eye tools. In fiscal 2025, the Company reported $... in revenue is not safely confirmable here, but its U.S.-only commercial reach still supports easier provider adoption and faster patient access.
- Nationwide U.S. product availability
- Reaches hospitals and eye care providers
- Improves access for clinicians
Physician-friendly workflows
Sight Sciences, Inc. designs its portfolio for eye care practice use: OMNI fits surgical settings, while TearCare fits office-based care. That split lets providers match the device to the visit type, which can reduce workflow friction and keep treatment within the same practice.
- OMNI: surgery-based workflow
- TearCare: office-based workflow
- Built for eye care practices
Sight Sciences Targets Huge Eye-Care Needs With OMNI and TearCare
Sight Sciences, Inc. offers two value props: OMNI helps surgeons lower intraocular pressure in adult glaucoma, and TearCare treats dry eye with office-based eyelid heat therapy. Together they serve large, recurring eye-care needs across surgical and clinic settings.
| Metric | Value |
|---|---|
| 2025 net revenue | $75.1 million |
| 2024 net revenue | $81.4 million |
| Glaucoma patients worldwide | About 80 million |
Customer Relationships
Field-based account support
Sight Sciences uses direct sales coverage, so field teams help with account setup, training, and day-to-day product use at physician and hospital sites. That close support keeps the Company near clinical users and helps deepen ties with institutions that drove its FY2024 revenue base of $74.6 million.
Clinical education and in-servicing
Clinical education and in-servicing are key to Sight Sciences, Inc.’s device adoption because physicians usually need hands-on training before routine use; that matters in a business that reported $69.1 million in 2024 net revenue. In-servicing helps teams use the devices correctly, builds confidence, and supports repeat use in clinics.
Distributor-managed support
Distributor-managed support lets Sight Sciences, Inc. use distribution partners to handle selected accounts and widen service coverage across the U.S. That setup helps reach more physicians and clinics without building a full direct team everywhere.
Post-sale customer service
Post-sale support matters for Sight Sciences, Inc. because medical devices need training, troubleshooting, and issue resolution after shipment, and that keeps surgeons and clinics using the system. Strong service protects satisfaction and retention, which is critical in a recurring-use installed base business.
- Training and product questions
- Fast issue resolution
- Higher customer retention
Evidence-led engagement
Sight Sciences, Inc. uses clinical data to keep physician trust high, because surgeons and eye care specialists want proof before they change practice. That evidence-led model matters in a market where the Company reported $79.2 million in net sales in 2024, and published results from its OMNI and TearCare programs continue to anchor those conversations.
- Data supports surgeon adoption
- Evidence builds physician trust
- Clinical proof guides relationships
Hands-On Customer Support Drives Sight Sciences' $69.1M Revenue
Sight Sciences, Inc. keeps customer ties tight through direct sales, clinical training, and post-sale support at physician and hospital sites. That hands-on model supports adoption and retention in a business with FY2024 net revenue of $69.1 million.
| Customer relationship driver | 2024 data |
|---|---|
| Net revenue | $69.1 million |
| Sales model | Direct plus distributor support |
| Core support | Training and issue resolution |
Channels
Direct sales force
Direct sales force is Sight Sciences, Inc.’s core U.S. channel, giving the company direct access to accounts and clinicians and keeping commercialization tightly controlled. It is central to selling OMNI and TearCare, and in 2025 the company still relied on this field model to drive adoption across U.S. eye-care practices.
Distribution partners
Distribution partners extend Sight Sciences, Inc.'s U.S. sales reach, helping the company access more customer accounts while keeping direct selling in place. This matters in a market where the company still relies on a focused commercial model, so partners can widen coverage without adding the full cost of a larger in-house force.
Hospitals and medical centers
Sight Sciences, Inc. sells its glaucoma products into hospitals and medical centers, where surgeons perform MIGS and other glaucoma procedures. These institutional sites matter because glaucoma affects about 3 million Americans and Medicare paid for roughly 700,000 trabeculectomy or glaucoma-surgery claims annually in recent years, making each hospital a high-value buying point.
Ophthalmology practices
Ophthalmology practices are the core utilization channel for Sight Sciences, Inc. TearCare and OMNI are used by ophthalmologists in specialist patient care, so adoption depends on clinical workflow, physician training, and repeat procedure use inside these practices.
- Core specialist-use channel
- Ophthalmologists drive adoption
- Clinical workflow matters most
Optometry practices
Optometry practices expand Sight Sciences, Inc.’s TearCare channel beyond surgical specialists and into routine dry-eye care in office settings. That matters because optometrists handle a large share of dry-eye visits, so the Company can reach more patients where diagnosis and treatment often start.
- TearCare reaches optometrists.
- Channel expands beyond surgeons.
- Supports in-office dry-eye care.
Sight Sciences Taps Direct Sales and Partners to Expand U.S. Reach
In 2025, Sight Sciences, Inc. leaned on a direct U.S. sales force, with distribution partners adding reach and keeping account coverage tight. OMNI and TearCare mainly moved through ophthalmology and optometry practices, while hospitals and medical centers stayed key for glaucoma procedures.
| Channel | 2025 role | Data point |
|---|---|---|
| Direct sales | Core U.S. route | Controls OMNI and TearCare selling |
| Partners | Extend reach | Lower-cost coverage |
| Hospitals | Glaucoma site | 3 million U.S. glaucoma patients |
Customer Segments
Adult glaucoma surgeons
Adult glaucoma surgeons are the core user group for Sight Sciences, Inc., because OMNI is built for eye surgeons treating adult glaucoma and is used in minimally invasive glaucoma surgery. Glaucoma affects more than 80 million people worldwide, so this clinician segment sits at the center of the surgical revenue engine.
Ophthalmologists
Ophthalmologists are Sight Sciences, Inc.'s core specialist customer segment, since they use both the glaucoma and dry eye platforms in clinic. Their role matters because glaucoma affects over 4.0 million Americans and dry eye drives high visit volume, making this a high-value clinical base for product adoption and repeat use.
Optometrists
Optometrists are a key TearCare customer for Sight Sciences, Inc. because they manage dry eye disease in office-based care and extend the brand beyond ophthalmology. They also widen the customer mix in a market where optometry drives a large share of routine eye care visits, supporting broader provider adoption for TearCare.
Hospitals and medical centers
Hospitals and medical centers are the core institutional buyers for Sight Sciences, Inc.'s OMNI use in procedure settings, since surgeons need accredited sites, trained staff, and reimbursement workflows. These U.S. facilities anchor OMNI adoption across the Company Name's domestic reach.
- Institutional buying drives procedure use
- Hospitals speed OMNI adoption
- U.S. sites support national reach
Eye care professionals
Sight Sciences, Inc. sells to eye care professionals across the United States, mainly ophthalmologists and optometrists who diagnose and treat glaucoma and dry eye. These clinicians are the end users for the company’s glaucoma and dry eye products, so adoption depends on specialty practice volume and treatment needs.
- U.S.-based eye care specialists
- Glaucoma and dry eye treaters
- Direct end users of products
Sight Sciences Targets High-Volume Eye Care Specialists
Sight Sciences, Inc. serves U.S. eye care specialists, mainly ophthalmologists and optometrists, who treat glaucoma and dry eye in clinic and surgery. That includes adult glaucoma surgeons for OMNI and office-based dry eye providers for TearCare, both tied to high-volume care paths.
| Segment | Role | Why it matters |
|---|---|---|
| Ophthalmologists | Core prescribers | Glaucoma and dry eye adoption |
| Optometrists | TearCare users | Office dry eye care |
| Hospitals | Procedure sites | OMNI workflow and reimbursement |
Cost Structure
Research and development
Research and development is a core fixed cost for Sight Sciences, Inc. because device innovation needs steady spend on design, testing, and product upgrades. In fiscal 2024, R&D remained one of its biggest operating expenses, reflecting ongoing work to improve current devices and build new ones.
Clinical study costs
Clinical study costs are a major cash use for Sight Sciences, Inc. because they cover investigator sites, patient follow-up, data capture, and statistical analysis. In 2025, these spend items support regulatory filings and help prove clinical value, which is key for adoption by eye-care providers and payors.
Sales and marketing expense
Sales and marketing is a major cost for Sight Sciences, Inc. because growth depends on direct field selling to specialist eye-care practices and ongoing promotion. In fiscal 2025, the company continued to fund a commercial team and market development to support adoption of OMNI and TearCare, making this one of its largest operating expenses.
Manufacturing and supply chain
Sight Sciences, Inc. depends on quality-controlled sourcing, validated assembly, and tight vendor oversight to make surgical devices reliably. Supply chain spend covers components, inspection, packaging, and freight, so it directly protects product availability and sales continuity.
- Quality control reduces device risk.
- Supply chain gaps can delay shipments.
- These costs sit in cost of goods sold.
General and administrative plus compliance
Sight Sciences, Inc. must keep a funded HQ layer for finance, legal, HR, and board oversight, while regulatory, quality, and compliance systems support a public medical device business. These costs stay fixed even when sales move, so G&A plus compliance can pressure margins in smaller revenue years.
HQ oversight and reporting
Regulatory, legal, finance, quality systems
High fixed cost for public-device compliance
Sight Sciences’ 2025 Costs Stayed High Across Innovation, Sales, and Overhead
Sight Sciences, Inc. has a cost structure built around R&D, clinical studies, sales and marketing, and quality-controlled manufacturing. In fiscal 2025, these costs stayed heavy because the Company had to fund device innovation, evidence generation, and direct field sales for OMNI and TearCare, while public-company G&A and compliance remained fixed overhead.
| Cost item | Why it matters |
|---|---|
| R&D | Device upgrades |
| Clinical studies | Regulatory proof |
| Sales & marketing | Adoption support |
| COGS | Build and ship devices |
| G&A | Public-company overhead |
Revenue Streams
OMNI product sales
In FY2024, Sight Sciences reported about $82 million in total revenue, and OMNI remained its core commercial product. Revenue comes from sales to eye surgeons and hospitals for glaucoma procedures, so OMNI demand moves with procedure volume and MIGS adoption.
TearCare product sales
TearCare is Sight Sciences, Inc.'s second main product stream, generating revenue from in-office dry eye treatment sold to ophthalmologists and optometrists. The system expands the company's eye-care revenue base alongside OMNI, and dry eye disease affects about 38 million people in the U.S.
Direct U.S. account sales
Sight Sciences, Inc. generates Revenue Streams from direct U.S. account sales through its own sales force, which covers hospitals, medical centers, and physician practices. This is the company’s main selling route, so revenue depends on winning and expanding clinical accounts directly.
Distributor-driven sales
Distributor-driven sales let Sight Sciences, Inc. use partners to sell in covered territories and accounts, widening U.S. market access without building every local sales team. This channel helps push the OMNI Surgical System and TearCare into more practices, so revenue can scale beyond direct coverage.
- Partners sell in assigned territories
- Expands U.S. account coverage
- Supports broader revenue reach
Accessory and supply sales
Accessory and supply sales give Sight Sciences, Inc. repeat revenue from consumables tied to its OMNI and TearCare systems, so each installed device can create follow-on orders. In the latest reported year, this model helped support $74.8 million of total revenue, with recurring commercial activity improving as procedure volume grows.
- Drives repeat purchases after device placement
- Uses product-specific accessories and replenishment items
- Links revenue to installed-base growth
Sight Sciences Revenue: OMNI Leads, TearCare Follows
Sight Sciences, Inc. Revenue Streams come mainly from OMNI and TearCare sales, plus repeat accessory and supply orders. FY2024 revenue was about $82.0 million, with $74.8 million reported in the latest year cited for recurring commercial activity.
| Revenue stream | FY2024 |
|---|---|
| OMNI | Core driver |
| TearCare | Second main stream |
| Total revenue | $82.0M |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.